https://prabadinews.com/
  • October 7, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

Donanemab-Azbt Receives FDA Label Update With New Dosing for Alzheimer Disease

Donanemab-Azbt Receives FDA Label Update With New Dosing for Alzheimer Disease

FDA approves a new dosing schedule for donanemab, enhancing safety and efficacy in treating early symptomatic Alzheimer disease.

administrator

Related Articles